In the spotlight
The continued burden of 新型冠状病毒肺炎 for the immunocompromised
新型冠状病毒肺炎
疫苗 and Immune Therapies
立博客户端app下载的目标是开发和提供变革性疫苗和抗体, providing long-lasting immunity to millions of people, where the burden of disease is greatest.
首页 / Our therapy areas / 疫苗 and Immune Therapies
Our commitment
立博客户端app下载致力于开发和提供变革性疫苗和抗体, providing long-lasting immunity for millions of people, where the burden of disease is greatest. During the 新型冠状病毒肺炎 pandemic, 立博客户端app下载在真正的全球努力中发挥了重要作用，以应对前所未有的新挑战.1 立博客户端app下载将继续推进疫苗和免疫疗法方面的科学研究，并与合作伙伴合作，推动改善公共卫生，确保立博客户端app下载的科学惠及数百万人.
Our focus areas
To achieve our ambition, 立博客户端app下载正在优化疫苗和抗体的潜力，以确保不让任何患者掉队. 立博客户端app下载正在设计下一代疫苗，这些疫苗有可能产生有效和持久的免疫反应. At the same time, we are pioneering novel approaches to develop highly targeted, 长效 antibodies, optimised with our half-life extension technology.2 We focus on a range of pathogens, including SARS-CoV-2,3 流感4 和RSV.5
Complementary approach
疫苗 for active immunisation; antibodies for passive immunisation for those who can’t mount an immune response
技术
Innovative next-generation technologies for vaccines; accelerated human antibody discovery, 长效, high-yield manufacturing for antibodies.
病原体
SAR-CoV-2, 流感, RSV & 除了
Our commitment to combatting coronavirus (新型冠状病毒肺炎) disease
立博客户端app下载继续致力于发现和开发抗击新型冠状病毒肺炎的新方法, 重点是保护最脆弱的患者，他们仍然受到新型冠状病毒肺炎的严重影响，并面临严重疾病的风险.
立博客户端app下载的人民
We are a passionate and dedicated team of scientists, 研究人员, 临床医生, medical and commercial professionals. We are breaking new boundaries with our discoveries, supported by our heritage, and empowered by our collaborations with commercial, academic and 政府ernment leaders across the world.
疫苗和免疫疗法单位是在一个新的和令人兴奋的疾病预防时代的最前沿. I am inspired by our team’s dedication to pushing the boundaries of science, helping to create a fairer and healthier future for all.
加入立博客户端app下载
立博客户端app下载的药品
立博客户端app下载无法在本网站上提供立博客户端app下载处方药的详细信息, in compliance with regulations. 立博客户端app下载的药物在个别国家获得了特定用途的批准，立博客户端app下载为患者提供的信息受当地法规的约束. 在某些情况下, 医疗保健专业人员和患者可以访问当地的立博平台网站，了解更多关于立博客户端app下载药物的信息. Please note that in some countries we are not allowed to provide very much, or sometimes any, 关于立博客户端app下载处方药的信息，所以你应该寻找其他值得信赖的来源. Always ask a healthcare professional for advice about medicines.
Evusheld
tixagevimab and cilgavimab
Fluenz Tetra/FluMist Quadrivalent
流感 vaccine live, intra-nasal
Synagis
palivizumab
立博客户端app下载的管道 for V&I
We are passionate about pushing the boundaries of science, 开发下一代疫苗和抗体，有能力改变立博客户端app下载预防和治疗地方性和大流行性病毒的方式.
疫苗 & Immune therapies (as of 25 April 2024)
第一阶段
二期
二期
第三阶段
模块项目
模块项目
最新消息
参考文献
1. 立博平台. 专家审查显示，Vaxzevria可提供与mRNA疫苗同样有效的预防新型冠状病毒肺炎住院和死亡的保护[最后访问:2022年10月]. Available from: http://www.AstraZeneca.com/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19.html.
2. 立博平台 news release. 新型冠状病毒肺炎长效抗体(LAAB)组合AZD7442快速进入III期临床试验.: Last accessed: October 2022. Available from: http://www.AstraZeneca.com/media-centre/press-releases/2020/covid-19-长效-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html.
3. Voysey米 等. 单剂给药及加强剂量时间对ChAdOx1 nCoV-19 (AZD1222)疫苗免疫原性和疗效的影响:4项随机试验的汇总分析. Lancet 2021; 397(10277):881–91.
4. ClinicalTrials.政府. EVUSHELD在海湾合作委员会国家(EVOLVE)实际环境中作为暴露前预防的临床应用:最后访问日期:2022年10月. Available from: http://clinicaltrials.政府/ct2/show/NCT05315323.
5. ClinicalTrials.政府. MEDI8897预防健康晚早产儿和足月儿医学护理下RSV LRTI的安全性和有效性研究(MELODY)[最后访问:October 2022]. Available from: http://clinicaltrials.政府/ct2/show/NCT03979313
Veeva ID: Z4-62731
日期 of preparation: March 2024